ALK-Abelló A/S
ALK-B
Pozycja w akcjach
#2351
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Cena akcji
$37.79
Kapitalizacja rynkowa
$8.38B
Zmiana (1 dzień)
4.29%
Zmiana (1 rok)
15.32%
Kraj
DK
Handel ALK-Abelló A/S (ALK-B)
Kategoria
Healthcare
EPS dla ALK-Abelló A/S (ALK-B)
EPS na dzień June 2026 TTM: $0.97
Według najnowszych raportów finansowych i ceny akcji firmy ALK-Abelló A/S, obecny EPS (TTM) wynosi $0.97. Na koniec roku 2023 firma miała EPS w wysokości $0.33, wzrost w porównaniu do do EPS z roku 2022, który wynosił $0.22.
Historia EPS dla ALK-Abelló A/S od 2004 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $0.97 | 89.90% |
| 2024 | $0.51 | 57.63% |
| 2023 | $0.33 | 48.86% |
| 2022 | $0.22 | 43.10% |
| 2021 | $0.15 | 744.75% |
| 2020 | $0.02 | -152.46% |
| 2019 | $-0.03 | -71.20% |
| 2018 | $-0.12 | -7.06% |
| 2017 | $-0.13 | -165.80% |
| 2016 | $0.20 | -24.04% |
| 2015 | $0.26 | 68.67% |
| 2014 | $0.15 | 159.15% |
| 2013 | $0.06 | 19.19% |
| 2012 | $0.05 | -71.86% |
| 2011 | $0.18 | 50.86% |
| 2010 | $0.12 | 2.37% |
| 2009 | $0.11 | 26.98% |
| 2008 | $0.09 | -34.81% |
| 2007 | $0.14 | 549.06% |
| 2006 | $0.02 | -99.37% |
| 2005 | $3.39 | 147.07% |
| 2004 | $1.37 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | 1,688.33% |
US
|
|
| $-7.98 | -923.95% |
US
|
|
| $-5.29 | -646.21% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 2,764.22% |
NL
|
